The Quantellect read.As of Nov 19, 2026, 10 active firms cover Sabra Healthcare REIT Inc: 3 rate it Buy or better, 7 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets are tightly clustered, $19.00 to $25.00, so the covering firms are broadly aligned. The average target of $21.33 sits 3% above the current $20.62. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.16 next quarter toward $0.67 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Neutral
Strong Buy00%
Buy330%
Neutral770%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$21.33
+3.5% upside
Average target across 9 active firms as of Nov 19, 2026 vs $20.62 current
Highest Target$25.00
Average Target$21.33
Lowest Target$19.00
Detailed analyst forecasts for SBRA
Showing 1–12 of 12 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 3 of 10 active firms rate SBRA a Buy (7 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SBRA EPS & revenue forecast
EPS · NEXT QUARTER
$0.16
Range $0.16 – $0.16 · 1 analysts · -0% YoY
Next period, 1 analysts expect Sabra Healthcare REIT Inc to earn $0.16 a share (range $0.16 – $0.16), versus $0.16 a year earlier. Full-year consensus is $0.32, growing to $0.67 the year after.
REVENUE · NEXT QUARTER
$257.9M
Range $241.1M – $294.7M · 1 analysts · +16% YoY
Revenue is expected to reach $257.9M (range $241.1M – $294.7M), +16.3% year-over-year. Full-year consensus is $945.1M, rising to $1.1B next year.
Top analysts covering Sabra Healthcare REIT Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SBRA.
#1
Nicholas Yulico
Scotiabank · Rank #77
Neutral
$20.00-3.0% to target
Overall win rate
53%
+ Follow
#2
John Kilichowski
Wells Fargo · Rank #103
Buy
$23.00+11.5% to target
Overall win rate
50%
+ Follow
#3
Richard Hightower
Barclays · Rank #184
Neutral
$21.00+1.8% to target
Overall win rate
45%
+ Follow
#4
Michael Lewis
Truist Securities · Rank #243
Buy
$24.00+16.4% to target
Overall win rate
43%
+ Follow
#5
Aaron Hecht
JMP Securities · Rank #299
Buy
$25.00+21.2% to target
Overall win rate
47%
+ Follow
SBRA stock forecast FAQ
What is SBRA's average 12-month price target?+
The 9 active firms with a live target average $21.33 for Sabra Healthcare REIT Inc over the next 12 months, ranging from a $25.00 high to a $19.00 low, as of Nov 19, 2026.
Is SBRA stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 10 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 7 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SBRA?+
The Street-high target is $25.00 (Citizens), and the Street-low is $19.00 (Citigroup). The average of all 9 active-firm targets is $21.33.
How many active Wall Street firms cover SBRA?+
10 active firms have a recognized rating on Sabra Healthcare REIT Inc as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SBRA?+
Among analysts who currently cover SBRA, Nicholas Yulico of Scotiabank has the strongest overall Quantellect track record (Rank #77). Their current call is Neutral with a $20.00 target.
What is Sabra Healthcare REIT Inc's projected EPS for next quarter?+
The consensus estimate is $0.16 per share (range $0.16 – $0.16) across 1 analysts. Full-year EPS is projected at $0.32, rising to $0.67 the following year.
How much revenue is Sabra Healthcare REIT Inc expected to report next quarter?+
Consensus revenue is $257.9M (range $241.1M – $294.7M). Full-year revenue is projected at $945.1M, growing to $1.1B next year.
Have analysts been upgrading or downgrading SBRA lately?+
As of Nov 19, 2026, 3 of 10 active firms rate SBRA a Buy (7 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SBRA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.